Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT03993353
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    200 mg intravenously every 3 weeks
  • Tadalafil — DRUG
    10 mg by mouth daily

Study Details

This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.

Key Dates

Start date
Apr 7, 2020
Status verified
Jan 2026
Primary completion
Apr 16, 2022
Completion
Jan 9, 2024

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tadalafil and Pembrolizumab
    Tadalafil for up to 12 months and pembrolizumab for up to 24 months.

Primary Outcome Measure

Rate of Dose Limiting Toxicity (DLT) [ Time Frame: 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSD Moores Cancer CenterLa JollaCalifornia92093-

Related coverage on Hipa.ai

Find similar trials in La Jolla, CA

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
UCSD Moores Cancer Center· La Jolla, CA

Related Studies